Bispecific Anti-CD28 x Anti-CD22 antibodies and uses thereof

PH12021551401B1Active Publication Date: 2026-08-14REGENERON PHARMACEUTICALS INC
0 Cites 0 Cited by

Patent Information

Application Number
PH12021551401
Authority / Receiving Office
PH · PH
Patent Type
Patents
Current Assignee / Owner
Filing Date
2021-06-14
Publication Date
2026-08-14
Estimated Expiration
2041-06-14
Patent Text Reader

Abstract

The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen- binding molecule that specifically binds human CD-22. In certain embodiments, the bispecific antigen- binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD-22, such as B-cell lymphomas. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and / or therapeutically beneficial.
Need to check novelty before this filing date? Find Prior Art